• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Intensity Therapeutics Provides Update On Phase 2 Presurgical Breast Cancer INVINCIBLE-4 Study; 71.4% Of Patients Who Received INT230-6 Prior To Standard Of Care Achieved A Pathological Complete Response

    Benzinga·03/12/2026 11:49:31
    Listen to the news
    • Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care ("SOC") ("Cohort A") achieved a pathological complete response ("pCR") whereas two (2) out of six (6) (33%) patients in the SOC arm alone ("Cohort B") achieved a pCR, with one patient still to be evaluated.
    • Forty-four percent (44%) fewer grade 3 or higher Adverse Events ("AEs") were observed in Cohort A compared to Cohort B.
    • A protocol amendment has been submitted to the Swiss Agency for Therapeutic Products ("Swissmedic"), Switzerland's regulatory authority, and the Swiss Ethics Committee to resume enrollment.